clinical trial · NCT06947993
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Atopic DermatitisGHZ339Placebo
brief summary
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
started
May 16, 2025
primary completion
Nov 27, 2028
completion
Dec 22, 2028
last updated
Dec 22, 2025
detailed description
This is a multicenter, randomized, double-blind, placebo-controlled Phase II platform study to investigate the efficacy and safety of several interventions in participants with moderate to severe AD.
The first intervention planned to be evaluated is GHZ339. Participants will be randomly assigned to one of the study arms.
official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol